Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns about signs of weakness in sales of its popular diabetes and weight-loss ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

According to Eli Lilly: Zepbound is available for people without ... People with a personal or family history of medullary thyroid carcinoma (MCT) should not take Zepbound. It is also unsuitable ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

During your appointment, the healthcare professional reviews your medical history, discusses any ... What is the cost of Zepbound? While Eli Lilly doesn’t offer specific pricing information ...

The single-action agents launched by Danish pharmaceutical company Novo Nordisk and American pharmaceutical company Eli Lilly, Wigobi and Zepbound ... launches digital history museum project ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?